High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol

C. R. Nichols, J. Andersen, H. M. Lazarus, H. Fisher, J. Greer, E. A. Stadtmauer, P. J. Loehrer, D. L. Trump

Research output: Contribution to journalArticlepeer-review

154 Scopus citations

Abstract

Purpose: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. Patients and Methods: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. Results: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. Conclusions: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

Original languageEnglish (US)
Pages (from-to)558-563
Number of pages6
JournalJournal of Clinical Oncology
Volume10
Issue number4
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: An Eastern Cooperative Oncology Group protocol'. Together they form a unique fingerprint.

Cite this